2mpg
From Proteopedia
(Difference between revisions)
												
			
			| Line 1: | Line 1: | ||
| ==Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue== | ==Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue== | ||
| - | <StructureSection load='2mpg' size='340' side='right' caption='[[2mpg]], [[NMR_Ensembles_of_Models | 35 NMR models]]' scene=''> | + | <StructureSection load='2mpg' size='340' side='right'caption='[[2mpg]], [[NMR_Ensembles_of_Models | 35 NMR models]]' scene=''> | 
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[2mpg]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[2mpg]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2MPG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2MPG FirstGlance]. <br> | 
| </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=AIB:ALPHA-AMINOISOBUTYRIC+ACID'>AIB</scene></td></tr> | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=AIB:ALPHA-AMINOISOBUTYRIC+ACID'>AIB</scene></td></tr> | ||
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">INS ([ | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">INS ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2mpg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2mpg OCA], [https://pdbe.org/2mpg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2mpg RCSB], [https://www.ebi.ac.uk/pdbsum/2mpg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2mpg ProSAT]</span></td></tr> | 
| </table> | </table> | ||
| == Disease == | == Disease == | ||
| - | [[ | + | [[https://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:[https://omim.org/entry/176730 176730]].<ref>PMID:3470784</ref> <ref>PMID:2196279</ref> <ref>PMID:4019786</ref> <ref>PMID:1601997</ref>   Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:[https://omim.org/entry/125852 125852]]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:18192540</ref>   Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:[https://omim.org/entry/606176 606176]]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.<ref>PMID:17855560</ref> <ref>PMID:18162506</ref>   Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:[https://omim.org/entry/613370 613370]]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.<ref>PMID:18192540</ref> <ref>PMID:18162506</ref> <ref>PMID:20226046</ref>   | 
| == Function == | == Function == | ||
| - | [[ | + | [[https://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.  | 
| <div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| == Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 23: | ||
| ==See Also== | ==See Also== | ||
| - | *[[ | + | *[[Insulin 3D Structures|Insulin 3D Structures]] | 
| == References == | == References == | ||
| <references/> | <references/> | ||
| Line 29: | Line 29: | ||
| </StructureSection> | </StructureSection> | ||
| [[Category: Human]] | [[Category: Human]] | ||
| + | [[Category: Large Structures]] | ||
| [[Category: Jiracek, J]] | [[Category: Jiracek, J]] | ||
| [[Category: Kosinova, L]] | [[Category: Kosinova, L]] | ||
Revision as of 15:18, 2 June 2021
Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue
| 
 | |||||||||||
